Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Tupelo, MS
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Kansas City, MO
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Nyack, NY
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Nyack, NY
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Goldsboro, NC
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
High Point, NC
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Bismarck, ND
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Middletown, OH
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Charleston, SC
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Austin, TX
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Dallas, TX
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Tyler, TX
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Clinical Research Facility
mi
from
Lacey, WA
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Clinical Research Facility
mi
from
Lacey, WA
Click here to add this to my saved trials
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/14/2017
Research Site
mi
from
Krasnodar,
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/14/2017
Research Site
mi
from
Krasnodar,
Click here to add this to my saved trials
Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia
A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.
Status: Enrolling
Updated:  11/15/2017
Children's Medical Center of Dallas
mi
from
Dallas, TX
Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia
A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.
Status: Enrolling
Updated: 11/15/2017
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Status: Enrolling
Updated:  11/29/2017
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Status: Enrolling
Updated: 11/29/2017
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Status: Enrolling
Updated:  11/29/2017
Columbia University Medical Center
mi
from
New York, NY
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT
Status: Enrolling
Updated: 11/29/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells
Status: Enrolling
Updated:  11/30/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants
Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells
Status: Enrolling
Updated: 11/30/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Tissue Sample Collection From Patients With Fanconi Anemia
Fanconi Anemia Cancer Cell Repository
Status: Enrolling
Updated:  11/30/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Tissue Sample Collection From Patients With Fanconi Anemia
Fanconi Anemia Cancer Cell Repository
Status: Enrolling
Updated: 11/30/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplant for Bone Marrow Failure Syndromes
Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Stem Cell Transplant for Bone Marrow Failure Syndromes
Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
Status: Enrolling
Updated:  12/19/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
Status: Enrolling
Updated: 12/19/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
New York Medical College
mi
from
Valhalla, NY
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
MBSR for Pain Catastrophizing in SCD
A Mindfulness-based Intervention For Pain Catastrophizing In Sickle Cell Disease
Status: Enrolling
Updated:  12/27/2017
Duke University School of Nursing
mi
from
Durham, NC
MBSR for Pain Catastrophizing in SCD
A Mindfulness-based Intervention For Pain Catastrophizing In Sickle Cell Disease
Status: Enrolling
Updated: 12/27/2017
Duke University School of Nursing
mi
from
Durham, NC
Click here to add this to my saved trials
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  1/4/2018
US National Institutes of Health - National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 1/4/2018
US National Institutes of Health - National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Gainesville, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Miami, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Orlando, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Boise, ID
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Iowa City, IA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Louisville, KY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Orleans, LA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Boston, MA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Kansas City, MO
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Livingston, NJ
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Livingston, NJ
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials